Answers are grounded in this paper and cite their sources.
Introduction: Prior to transcutaneous aortic valve replacement (TAVR), a CT is performed (TAVR-CT). With modification, the CT exam can measure myocardial extracellular volume (ECV). A small increase in ECV occurs in severe aortic stenosis. A large increase in ECV occurs when transthyretin cardiac amyloidosis (ATTR-CA) co-exists. We sought to determine the prognostic potential of ECV in severe aortic stenosis and test the utility of threshold ECV to instigate screening for ATTR-CA. Methods: Tc-pyrophosphate (PYP) imaging was performed. The primary end point was all cause mortality. Conclusion: In severe AS, elevated ECV was a risk for all cause mortality, but this was not related to co-existent ATTR-CA. Threshold-ECV testing for ATTR-CA demonstrated a low yield. Threshold testing may therefore not be warranted in all severe AS patients with an ECV ≥ 31 %.
No takes yet. Share an insight, caveat, or question.
McShane et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: